BMJ  2008;336:56-57 (12 January), doi:10.1136/bmj.39454.496748.80

Editorials

Parliamentary review asks NICE to do better still

Out goes the arbitrary funding threshold: in come NICE "directives"

The first 150 words of the full text of this article appear below.

On Wednesday 9 January 2008, the House of Commons health select committee published the report of its second inquiry into the National Institute for Health and Clinical Excellence (NICE).1 The committee’s first inquiry into NICE was published six years ago,2 just three years after the institute’s launch. Much has happened since the initial inquiry. The institute is now well established and is a core policy driver within the National Health Service in England and Wales (its remit does not cover Scotland), and we know much more about how it operates. Moreover, the working environment of the institute has changed with, for instance, the publication of the Cooksey report on funding for health research in the United Kingdom,3 the introduction of legislation making NICE technology appraisals essentially compulsory,4 the involvement of the courts in a legal challenge to NICE,5 and most recently the Office of Fair Trading’s critical review of how . . . [Full text of this article]

Joe Collier, emeritus professor in medicines policy

1 St George’s Hospital, University of London, SW17 0RE

jcollier@sgul.ac.uk


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to StumbleUpon StumbleUpon   Add to Technorati Technorati    What's this?

Relevant Article

Value based pricing for NHS drugs: an opportunity not to be missed?
Karl Claxton, Andrew Briggs, Martin J Buxton, Anthony J Culyer, Christopher McCabe, Simon Walker, and Mark J Sculpher
BMJ 2008 336: 251-254. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

  • Clement, F. M., Harris, A., Li, J. J., Yong, K., Lee, K. M., Manns, B. J. (2009). Using Effectiveness and Cost-effectiveness to Make Drug Coverage Decisions: A Comparison of Britain, Australia, and Canada. JAMA 302: 1437-1443 [Abstract] [Full text]  
  • Minhas, R., Patel, K. C. (2008). From rationing to rational: the evolving status of NICE. JRSM 101: 436-442 [Full text]  
  • Claxton, K., Briggs, A., Buxton, M. J, Culyer, A. J, McCabe, C., Walker, S., Sculpher, M. J (2008). Value based pricing for NHS drugs: an opportunity not to be missed?. BMJ 336: 251-254 [Full text]  



Access jobs at BMJ Careers
Whats new online at Student 

BMJ